Download the slides

---

Related articles :

• Fostemsavir
  • AI438011 Study
• TAF
  • 292-0102 Study
  • 299-0102 Study
• Doravirine
  • MK1439007 Study
• Cabotegravir
  • LATTE Study
• BMS-955176
  • AI468002 Study

---

Table of contents

Fostemsavir, prodrug of temsavir
(attachment inhibitor)
AI438011 Study : Fostemsavir Phase II
Original article : Lalezari J. Lancet HIV 2015; 2:e427-37 ; Thompson M, CROI 2015, Abs. 545
Last update : 12/10/2015

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

• Virologic response rates (mITT and observed) and immunologic responses were similar across the fostemsavir and ATV/r arms through Week 48
• All fostemsavir doses were generally well tolerated with no dose-response safety signals reported
• Continuation dose of fostemsavir 1200 mg QD for the Phase IIb study
• Phase III study in heavily treatment-experienced patients with limited therapeutic options
  • Phase III dose : 600 mg BID
  • Subjects enrolled regardless of baseline susceptibility to temsavir
  • A retrospective analysis will be conducted to determine whether a baseline phenotypic assay is necessary in the future

Design :

• Phase IIb , randomised, active-controlled, bl inded -to-fostemsavir dose
• ARV-experienced patients, > 18 years, HIV RNA > 1,000 c/ mL , CD4 cell count > 50/mm3
• Susceptibility to RAL, TDF and ATV
• Temsavir IC 50 < 0.1 μM (100 nM ) by screening Phenosense ® entry assay

Objective :

• Primary endpoints (W24) :
  • % HIV-1 RNA < 50 c/ mL
  • % of SAEs and AEs leading to discontinuation
• Secondary endpoints (W48) :
  • %HIV-1 RNA < 50 c/ mL
  • Change in CD4 T- cell count from baseline
  • % SAEs and AEs leading to discontinuation

Baseline characteristics and patient disposition

Fostemsavir 7 days of monotherapy
Mean change in HIV RNA from baseline (log 10 c/ml)

HIV RNA < 50 c/ mL or < 400 c/ mL at W24

HIV RNA < 50 c/ml at W24 by baseline HIV RNA (observed )

HIV RNA < 50 c/ mL or < 400 c/ mL at W48, mITT snapshot

HIV RNA < 50 c/ mL at W48, observed

Safety data through W48

* Anal abscess, herpes encephalitis, overdose (3), extrapulmonary tuberculosis (2), herpes zoster , abdominal pain, myalgia , spontaneous abortion, acute renal failure , cellulitis (2), lymphangitis , chronic cholecystitis , back pain, pneumonia , pyelonephritis , diarrhea , cholelithiasis , migraine
** Illegal substance use, extrapulmonary tuberculosis (3), acute renal failure , abdominal distension, flatulence, nausea , jaundice ; 6/7 AE leading to discontinuation in first 24 weeks

Grade 3-4 laboratory abnormalities (≥ 2 subjects )

Mean change from baseline at W48 in fasting lipids , mg/ dL

Back to Table of Contents